Preclinical studies are exploring the efficacy of these inhibitors, either as single agents or in combination with existing chemotherapies or targeted therapies, to overcome Bcl-2-mediated resistance in HCC [44–46]. The gene discussed is BCL2; the disease is hepatocellular carcinoma.